NCT02533544已完成不适用
Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B : a Real Life Multicenter Cohort Study in Korea
Myeong Jun Song1 个研究点 分布在 1 个国家目标入组 572 人开始时间: 2015年10月最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 572
- 试验地点
- 1
- 主要终点
- The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 48
研究概览
简要总结
This is an open-label, single arm cohort study to see efficacy and safety of tenofovir disoproxil fumarate (TDF) in naïve chronic hepatitis B, retrospectively and prospectively both.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
- •Adult male and non-pregnant, non-lactating female subjects, 19 years of age and older, based on the date of the screening visit. A negative serum pregnancy test at Screening is required for female subjects of childbearing potential (unless surgically sterile or greater than 2 years post-menopausal).
- •Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6 months)
- •Chronic hepatitis B with the following:
- •HBeAg-positive and HBeAb negative at Screening
- •Screening HBV DNA ≥ 1x 105 copies/mL
- •Screening serum ALT level ≥ ×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR
- •HBeAg-negative and HBeAb positive at Screening
- •Screening HBV DNA ≥ 1x 104 copies/mL
- •Screening serum ALT level ≥ ×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR
- •Cirrhosis at Screening
- •Screening HBV DNA ≥ 1x 104 copies/mL in HBeAg negative or
- •Screening HBV DNA ≥ 1x 105 copies/mL in HBeAg positive
- •Screening serum ALT level ≥ ×ULN and ≤ 10 ×ULN (by center laboratory range)
- •A patient who treating with TDF as a treatment-naïve for Hepatitis B. Treatment naïve subjects defined as no history of antiviral therapy or < 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue, including lamivudine or adefovir, clevudine, telbivudine, entecavir
- •Decompensated liver cirrhosis defined based on a Child-Turcotte-Pugh (CTP) score ≥ 7 (Child B and C) or presence with at least one episode of ascites, jaundice, hepatic encephalopathy or variceal bleeding
- •Any previous treatment with interferon (pegylated or non-pegylated) must have ended at least 6 months prior to the baseline visit
- •Must be willing and able to comply with all study requirements.
排除标准
- •Subjects who meet any of the following exclusion criteria are not to be enrolled in the study.
- •Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study.
- •Co-infection with HCV, HIV
- •Evidence of hepatocellular carcinoma (e.g. α-fetoprotein> 50 ng/mL or as evidenced by recent ultrasound or other standard of care measure)
- •Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible
- •Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance
- •Currently receiving therapy with cytotoxic agent, nephrotoxic agents, or agents capable of modifying renal excretion
- •Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.
研究组 & 干预措施
tenofovir disoproxil fumarate monotherapy
a group which treated with tenofovir disoproxil fumarate
干预措施: tenofovir disoproxil fumarate (Drug)
结局指标
主要结局
The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 48
时间窗: week 48
proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 48
The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 96
时间窗: Week 96
proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 96
次要结局
- The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at every visits(week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144)
- The proportion of the biochemical (alanine aminotransferase normalization) response of TDF for the treatment of chronic hepatitis B at Week 48 and 96(Week 48 and 96)
- The proportion of the serological response (loss of HBeAg and seroconversion to HBeAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96(Week 48 and 96)
- The proportion of the serological response (loss of HBsAg and seroconversion to HBsAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96(Week 48 and 96)
- The change from baseline in the decline of HBV DNA at every visits(week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144)
- The proportion of patients showing virological breakthrough at week 48 and 96(Week 48 and 96)
- The incidence of resistance of TDF among patients showing virological breakthrough at week 48 and 96(Week 48 and 96)
- The proportion of improvement of liver function including Child Score, Model for End-stage Liver Disease (MELD) score at Week 48 and 96(Week 48 and 96)
- The proportion of improvement of Fibrosis marker including Aspartate aminotransferase to Platelet Ratio Index(APRI) at Week 48 and 96(Week 48 and 96)
研究者
Myeong Jun Song
Assistant Professor
The Catholic University of Korea
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral TherapyHIV InfectionsNCT00352053Gilead Sciences87
已完成
2 期
Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.Chronic Hepatitis BNCT00298363Gilead Sciences112
进行中（未招募）
Unknown
Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B patientsEffectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B patientsInfections and InfestationsISRCTN80908109GlaxoSmithKline (China) Investment Co., Ltd.2,000
Unknown
3 期
The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected PatientsHIV InfectionsNCT00007436Gilead Sciences
已完成
4 期
Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis BChronic Hepatitis BNCT01277601Gilead Sciences751